Biocryst Pharmaceuticals INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersDurham, NC
US patents81
SAM.gov UEIMGXADJ6SCLJ5
CAGE code4GBX7
Incorporated inDE
LEI549300Z0INP1Z5NP6J59
- medicines
- treatments
- rare diseases
- hereditary angioedema
- three decades
- drug discovery
Named on the company’s own website, read JUL 29, 2026
Open positions
Openings read from Biocryst Pharmaceuticals INC’s own job board on Workday, last checked OCT 28, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- Sr. Paralegal - GeneralistUS_North Carolina_Remote · posted OCT 28, 2026
- VP, Global Clinical DevelopmentUS_North Carolina_Remote · posted OCT 28, 2026
- VP, BiostatisticsUS_North Carolina_Remote; US_Massachusetts_Boston Office · posted OCT 28, 2026
- Sales - Rare Disease Specialist (Los Angeles)US_North Carolina_Remote; US_California_Remote · posted OCT 27, 2026
- Sr. Clinical Data Manager (contract)US_North Carolina_Remote · posted OCT 18, 2026
- Regional Business DirectorUS_North Carolina_Remote; New York City; US_Massachusetts_Remote; US_New York_Remote; US_Maine_Remote; US_Massachusetts_Boston Office; US_New Hampshire_Remote; US_New Jersey_Remote; US_Connecticut_Remote; US_Rhode Island_Remote · posted OCT 16, 2026
- Contracts ManagerUS_North Carolina_Remote; USA Remote · posted OCT 16, 2026
- Regional Business DirectorUS_North Carolina_Remote; USA Remote; US_Michigan_Remote; US_Ohio_Remote; US_Illinois_Remote; US_Indiana_Remote · posted OCT 16, 2026
- Product Safety Associate - Postmarketing (Contract)US_North Carolina_Remote · posted OCT 16, 2026
- Rare Disease Specialist (営業担当) - 日本APAC_Japan · posted OCT 14, 2026
13 more on the company’s board
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
81 US patents granted 1996–2025, 30 of them in the five years to SEP 2025.
Pharmaceuticals 56Organic fine chemistry 24Measurement 1
- Crystalline salts of a plasma kallikrein inhibitorUS 12,344,585 · granted JUL 1, 2025
- Human plasma kallikrein inhibitorsUS 12,162,838 · granted DEC 10, 2024
- Antiviral treatmentsUS 12,121,503 · granted OCT 22, 2024
- Human plasma kallikrein inhibitorsUS 12,116,346 · granted OCT 15, 2024
- Imidazole-containing inhibitors of ALK2 kinaseUS 12,054,492 · granted AUG 6, 2024
Newest 5 shown · Granted to BioCryst Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Biocryst Pharmaceuticals INC | Durham | NC | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


